We can’t show the full text here under this license. Use the link below to read it at the source.
Dapagliflozin attenuates metabolic dysfunction-associated steatotic liver disease by inhibiting lipid accumulation, inflammation and liver fibrosis
Dapagliflozin reduces fatty liver disease by lowering fat buildup, inflammation, and liver scarring
AI simplified
Abstract
(DaPa) administration reduced liver fat accumulation in male diet-induced obese mice.
- DaPa may decrease oxidative stress and lipid peroxide levels in the liver.
- The reduction in oxidative stress is linked to increased levels of glutathione.
- DaPa is associated with lower levels of malondialdehyde and reactive oxygen species.
- The treatment appears to downregulate the inflammatory response in the liver.
- DaPa may also reduce liver fibrosis in the context of metabolic dysfunction.
AI simplified